Literature DB >> 20127825

Drug-polymer solubility and miscibility: Stability consideration and practical challenges in amorphous solid dispersion development.

Feng Qian1, Jun Huang, Munir A Hussain.   

Abstract

Drug-polymer solid dispersion has been demonstrated as a feasible approach to formulate poorly water-soluble drugs in the amorphous form, for the enhancement of dissolution rate and bioperformance. The solubility (for crystalline drug) and miscibility (for amorphous drug) in the polymer are directly related to the stabilization of amorphous drug against crystallization. Therefore, it is important for pharmaceutical scientists to rationally assess solubility and miscibility in order to select the optimal formulation (e.g., polymer type, drug loading, etc.) and recommend storage conditions, with respect to maximizing the physical stability. This commentary attempts to discuss the concepts and implications of the drug-polymer solubility and miscibility on the stabilization of solid dispersions, review recent literatures, and propose some practical strategies for the evaluation and development of such systems utilizing a working diagram. (c) 2010 Wiley-Liss, Inc. and the American Pharmacists Association

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20127825     DOI: 10.1002/jps.22074

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  61 in total

Review 1.  Challenges and Strategies in Thermal Processing of Amorphous Solid Dispersions: A Review.

Authors:  Justin S LaFountaine; James W McGinity; Robert O Williams
Journal:  AAPS PharmSciTech       Date:  2015-08-26       Impact factor: 3.246

2.  Use of Polyvinyl Alcohol as a Solubility Enhancing Polymer for Poorly Water-Soluble Drug Delivery (Part 2).

Authors:  Chris Brough; Dave A Miller; Daniel Ellenberger; Dieter Lubda; Robert O Williams
Journal:  AAPS PharmSciTech       Date:  2016-02-10       Impact factor: 3.246

3.  Solution behavior of PVP-VA and HPMC-AS-based amorphous solid dispersions and their bioavailability implications.

Authors:  Feng Qian; Jennifer Wang; Ruiling Hartley; Jing Tao; Raja Haddadin; Neil Mathias; Munir Hussain
Journal:  Pharm Res       Date:  2012-10       Impact factor: 4.200

4.  Influence of Low-Molecular-Weight Excipients on the Phase Behavior of PVPVA64 Amorphous Solid Dispersions.

Authors:  Kristin Lehmkemper; Samuel O Kyeremateng; Matthias Degenhardt; Gabriele Sadowski
Journal:  Pharm Res       Date:  2018-01-05       Impact factor: 4.200

5.  Processability of AquaSolve™ LG polymer by hot-melt extrusion: Effects of pressurized CO2 on physicomechanical properties and API stability.

Authors:  Mashan Almutairi; Bjad Almutairy; Sandeep Sarabu; Ahmed Almotairy; Eman Ashour; Suresh Bandari; Amol Batra; Divya Tewari; T Durig; Michael A Repka
Journal:  J Drug Deliv Sci Technol       Date:  2019-04-18       Impact factor: 3.981

Review 6.  Controlled release systems containing solid dispersions: strategies and mechanisms.

Authors:  Phuong Ha-Lien Tran; Thao Truong-Dinh Tran; Jun Bom Park; Beom-Jin Lee
Journal:  Pharm Res       Date:  2011-05-07       Impact factor: 4.200

7.  Getting physical to fix pharma.

Authors:  Patrick R Connelly; T Minh Vuong; Mark A Murcko
Journal:  Nat Chem       Date:  2011-08-23       Impact factor: 24.427

8.  Construction and Validation of Binary Phase Diagram for Amorphous Solid Dispersion Using Flory-Huggins Theory.

Authors:  Krishna Bansal; Uttam Singh Baghel; Seema Thakral
Journal:  AAPS PharmSciTech       Date:  2015-06-20       Impact factor: 3.246

9.  An investigation of nifedipine miscibility in solid dispersions using Raman spectroscopy.

Authors:  Sujinda Keratichewanun; Yasuo Yoshihashi; Narueporn Sutanthavibul; Katsuhide Terada; Jittima Chatchawalsaisin
Journal:  Pharm Res       Date:  2015-02-12       Impact factor: 4.200

10.  Amorphous solid dispersions of sulfonamide/Soluplus® and sulfonamide/PVP prepared by ball milling.

Authors:  Vincent Caron; Yun Hu; Lidia Tajber; Andrea Erxleben; Owen I Corrigan; Patrick McArdle; Anne Marie Healy
Journal:  AAPS PharmSciTech       Date:  2013-02-07       Impact factor: 3.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.